Fresh2 Group Ltd (FRES)vsWaters Corporation (WAT)
FRES
Fresh2 Group Ltd
$0.85
0.00%
HEALTHCARE · Cap: $2.97M
WAT
Waters Corporation
$365.36
-2.95%
HEALTHCARE · Cap: $34.91B
Smart Verdict
WallStSmart Research — data-driven comparison
Waters Corporation generates 22104% more annual revenue ($3.77B vs $16.98M). WAT leads profitability with a 11.9% profit margin vs 0.0%. WAT earns a higher WallStSmart Score of 50/100 (C-).
FRES
Avoid33
out of 100
Grade: F
WAT
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for FRES.
Margin of Safety
-84.6%
Fair Value
$178.29
Current Price
$365.36
$187.07 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 91.4% year-over-year
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Expensive relative to growth rate
Trading at 8.5x book value
ROE of 2.9% — below average capital efficiency
Operating margin of 2.8%
Comparative Analysis Report
WallStSmart ResearchBull Case : FRES
The strongest argument for FRES centers on Price/Book, Debt/Equity.
Bull Case : WAT
The strongest argument for WAT centers on Revenue Growth, Altman Z-Score. Revenue growth of 91.4% demonstrates continued momentum.
Bear Case : FRES
The primary concerns for FRES are EPS Growth, Market Cap, Profit Margin.
Bear Case : WAT
The primary concerns for WAT are PEG Ratio, Price/Book, Return on Equity. A P/E of 45.2x leaves little room for execution misses.
Key Dynamics to Monitor
FRES profiles as a value stock while WAT is a growth play — different risk/reward profiles.
FRES carries more volatility with a beta of 1.28 — expect wider price swings.
WAT is growing revenue faster at 91.4% — sustainability is the question.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
WAT scores higher overall (50/100 vs 33/100) and 91.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fresh2 Group Ltd
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Fresh2 Group Limited, a biotechnology company, researches, develops, markets, and sells multi-cancer screening and detection tests using cancer differentiation analysis technology and device to corporations and life insurance companies in the People's Republic of China. The company is headquartered in New York, New York.
Waters Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?